


Background & Innovation

Nanoscale tumor-derived small extracellular vesicles (sEVs) promote tumor growth and metastasis via interactions with immune cells (1). Our recent data demonstrate that tumor sEVs induce macrophage ($M\phi$) functions (2).

Mos are a heterogeneous population of myeloid cells of the immune system involved in a variety of physiological and pathological processes (3). Tumor-associated M1 (proinflammatory) or M2 (immunosuppressive) Mos are pivotal in the progression of inflammation-related cancers. Growing evidence shows crosstalk between tumor cells and Mos is involved in hepatic tumor progression (4). However, the ability of liver tumor-derived sEVs to influence Mo-related pro-tumor inflammatory processes is largely unknown.

Objective

Using the HepG2 liver tumor model we explored the hypothesis that HepG2 sEVs will induce Mo polarity, indicative of pro-tumor inflammatory processes.




Tumor Microenvironment

Methods

- Human THP-1 (ATCC® TIB-202[™]) and HepG2 cells were cultured in DMEM with 10% FBS media at 37°C and 5% CO2
- Human THP-1 (ATCC® TIB-202[™]) monocytes were converted to M¢s using phorbol myristate acetate.
- sEVs were isolated from the HepG2 media via differential ultracentrifugation. sEV concentration (µg protein mass/µl) was measured using a BCA assay (Thermo Scientific).
- Human IL-10 ELISA Max[™] Deluxe Set (BioLegend) and Human TNF-α Uncoated ELISA (Thermo Fisher) were used to test cytokine production in treated and untreated cells.
- A PrestoBlue[™] Cell Viability Reagent (Thermo Fisher) was used to determine the viability of $M\phi s$.
- Induction of key M1 (TNF- α), and M2 (IL-10) markers were evaluated.

Induction of Macrophages by Liver Tumor-Derived Small Extracellular Vesicles

Mackenzie J. Burroughs, Gina T. Bardi, and Joshua L. Hood M.D., Ph.D. University of Louisville, Department of Pharmacology and Toxicology & the James Graham Brown Cancer Center, Louisville, KY




ELISA dose response curves were constructed for IL-10 (**Fig. 1**) and TNF- α (**Fig. 2**) to guide the selection of an appropriate sEV concentration to use for subsequent experiments. Assessment of the immunosuppressive M2 cytokine IL-10 revealed that a dose of 0.1 μ g/ μ l significantly upregulated IL-10 production by THP-1 M\u00f6s (Fig. 1). However, upregulation of the proinflammatory M1 cytokine TNF- α only required 0.05 μ g/ μ l (**Fig. 2**). To conserve samples and avoid competing signals between overlapping TNF- α and IL-10 pathways (5,6), we opted to perform the remaining experiments using the 0.05 μ g/ μ l dose.

Subsequent ELISA experiments demonstrated that one independent batch of HepG2 sEVs significantly induced IL-10 (**Fig.3**) at the 0.05 μ g/ μ l dose, while a second batch did not (Fig.3) serving to highlight batch to batch variations. In contrast, normal plasma (np) sEVs did not increase IL-10 production (**Fig. 3**). TNF- α production was significantly induced by all np and HepG2 sEV lots and batches tested (**Fig.4**).

Use of RT-qPCR to evaluate induction of M1 or M2 M¢ polarization markers was consistent with ELISA data. Np sEVs (Fig. 5) induced less polarization markers than HepG2 sEVs (Fig. 6). Both types of sEVs favored induction of M1 polarization factors with HepG2's also trending toward induction of a few mixed M1/M2 and M2 markers. This is consistent with our previous melanoma sEV findings (2).

The long-term goals are 1. To establish whether liver tumorderived sEVs influence liver-associated Mo pro-tumor processes, and 2. Determine whether liver tumor-derived sEVs might be tuned to serve as personalized immunotherapeutic vaccines routed through liver-associated Mos. To achieve these goals, additional functional and sEV nanocarrier modification studies will be required.



Summary & Conclusions

Significance and Impact

References

Hood, J.L. and S.A. Wickline, A systematic approach to exosome-based translational nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2012 4(4): p. 458-67 Bardi, G.T., M.A. Smith, and J.L. Hood, Melanoma exosomes promote mixed M1 and M2 macrophage polarization. Cytokine, 2018. 105: p. 63-72. Genin, M. et. al. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer, 2015.

Yang et al. Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors. Death and Disease, 2018. 9:793:p 1-14. Wanidworanun, C. and W. Strober, Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol, 1993. 151(12): p. 6853-

Armstrong, L., N. Jordan, and A. Millar, Interleukin 10 (IL-10) regulation of tumour necrosis factor alpha (TNF-alpha) from human alveolar macrophages and peripheral blood monocytes. Thorax, 1996. 51(2): p. 143-9.

Acknowledgements

Research was supported by the University of Louisville Cancer Education Program NIH/NCI (R25-CA134283), The Elsa U. Pardee Foundation, and University of Louisville faculty start-up funds to J. L. Hood.